Objectives: According to clinical and comissioning guidelines for chronic rhinosinusitis (CRS), patients being referred to secondary care should have failed primary medical treatment with nasal douching (ND) and intranasal corticosteroids (INCS). The study objectives were to identify the rate of specific medical therapy in CRS patients and establish any differences in medication use, for both CRS and associated medical conditions, between CRS phenotypes.
| BACKGROUND
Chronic rhinosinusitis (CRS) is a common inflammatory disorder of the respiratory tract defined by the presence of either nasal blockage and/or nasal discharge as well as loss of smell and/or facial pain/pressure for 12 weeks or more; this must be corroborated with endoscopic findings (mucopus/polyps) and/or radiological findings (CT scan opacification in sinuses) 1 . Chronic rhinosinusitis affects a significant proportion of the adult population with a recent European study suggesting a prevalence of 11% in the UK 2 
. Longitudinal data from the Clinical Practice
Research Datalink (CPRD) show that 1% these affected adults receive treatment from their GP each year with an average of 4 GP visits 3 , and additionally this includes prescription of multiple medications with 91% receiving an antibiotic prescription 4 . There are no NICE guidelines, and although international guidelines exist, 1, 5 familiarity and uptake of them is not quantified. These guidelines recommend both intranasal corticosteroids (INCS) and saline irrigation/nasal douching (ND), for which there are strong recommendations for use, based on recent Cochrane reviews [6] [7] [8] .
Hospital Episode Statistics (HES) Data show that approximately
40 000 sinus operations are performed (mostly for CRS), in England and Wales each year, which is the progression of management when medical treatment in isolation has failed 9 . A recent ENT-UK commissioning guideline underpins the need for adequate medical management and compliance with ND and INCS use for at least 3 months before referral to secondary care and possible surgical intervention 10 . In a recent Canadian study, it was demonstrated that only 20% of adult patients who received a diagnosis of CRS within the previous 3 years and had not undergone sinus surgery, had utilised their INCS indicating approximately 80% had failed to use a single unit of INCS and thus identifying a gap in the quality of care 11 . Currently there are an estimated 120 000 secondary care outpatient encounters for CRS per year in England and Wales, 12 and this could represent an unnecessary burden if primary medical treatment is not being best utilised; extrapolating the above Canadian data that 80% of patients failed to achieve this would translate to a cost of over £15 million in secondary care referrals.
The aim of this specific analysis of the data from the Chronic Rhinosinusitis Epidemiology Study (CRES) was to quantify the use of medications specific to CRS and for other comorbidities at a point of contact with secondary care and thus determine the degree of compliance with optimal medical management of CRS prior to that contact.
| METHODS

| Study design and setting
The CRES was approved by the Oxford C Research Ethics Committee (Ref: 07/H0606/100), sponsored by the University of East
Keypoints
• Long-term topical therapy is the cornerstone to managing chronic rhinosinusitis (CRS).
• Current levels of compliance with nasal douching (ND) and intranasal corticosteroids (INCS) are likely to be poor.
• Clinicians in both primary and secondary care need to work together to encourage good compliance and ensure where possible guidelines are adhered to for best use of healthcare resources.
Anglia (UEA) and funded by the Anthony Long and Bernice Bibby
Trusts. Details of the full methods used for the whole study can be seen in the overview publication 13 . In summary, the CRES aimed to identify differences in socioeconomic variables and quality of life between patients with CRS and healthy controls and was conducted as a prospective case-control multicentre study across the UK involving 30 sites between 2007 and 2013; adoption of the study on to the NIHR portfolio in 2012 saw recruitment of over 600 participants in 1 year. Any patients presenting to secondary care ENT outpatient clinics and diagnosed with CRS (as defined by the criteria laid out in the European Position Paper on Rhinosinusitis and Nasal Polyps 1 (see above) by an Otorhinolaryngologist) were invited to complete the study questionnaire regardless of symptom or disease severity or duration, and regardless of any prior interventions. Control subjects were also recruited but do not form part of this specific analysis.
| Variables and data sources
The study-specific questionnaire (Appendix 2) was anonymous, and therefore, no consent was taken but implied through participation, as approved by the ethics committee. Participant information leaflets were provided. Patients were classified by subgroup of CRS (CRSsNPs, CRSwNPs or allergic fungal rhinosinusitis (AFRS) by an
Otorhinolaryngologist prior to completion of the questionnaire.
Questionnaires were either completed before leaving the clinic or taken home and returned by post in Freepost envelopes. The returned questionnaires were then scanned into a database electronically but the electronic records were then checked by two members of the research team for accurate correlation with the paper questionnaire and for missing data. The return rate for questionnaires during the NIHR portfolio phase of the study was 66%.
The study questionnaire included the question "Do you have any regular medications? Yes/No" followed by a free text box asking participants to list any current medication use. 
| Exclusion criteria
1. Patients unable to comprehend written English.
2.
Patients under the age of 18 years.
| Sample size calculation and statistical analysis
The sample size calculation was based on the primary outcome of the study, which was to look for common associations between socioeconomic factors and CRS. This is detailed in the overview publication of the study 13 . For the purposes of these analyses, we have used descriptive statistics; differences in the rates of medication use between groups were assessed by chi-squared tests.
| RESULTS
A total of 1470 participants' questionnaires were available for analysis; 1249 with CRS and 221 controls. The age range was 18-102 years (mean 52) with 54% who were male; further details of the demographics of the study participants are available in the study overview publication 13 .
| Participant flow
As detailed in Figure 1 , six participants had incomplete information in the medication section of the questionnaire, leaving 1243 participants. A total of 899 had answered positively to taking medications with a respective 850 having recorded details of medications taken.
PHILPOTT ET AL.
| 511
As the AFRS group was small, we have merged it with the CRSwNPs group and analysed only the two main CRS phenotypic groups and the controls.
| Missing data
Subjects identified in Figure 1 with missing data were excluded from the analysis in keeping with the primary aim of this analysis. Table 1 shows further details of the excluded cases based on the text box entries.
| Baseline currently used therapy for CRS
Only 1% of CRS participants reported current use of ND and only 15% of all CRS participants reported current use of INCS with a significantly higher uptake in the CRSwNPs group (18.4%) than the CRSsNPs group (11.8%) (P = .002); see Table 2 . Oral corticosteroid and antibiotic use at the time of participants completing the questionnaire was low (1%-3%). There is no evidence of a difference in social deprivation (as denoted by the index of multiple deprivation (IMD) between those prescribed CRS medication and those not (P > .05 for all comparisons; Table 2 ). Patients were also grouped into regional clusters to look for geographical variation. Using the following clusters, there were no significant signs of variation in uptake (P > .05): South of England and London, East Anglia, Midlands, North of England, Wales, Scotland (Table 3) . Table 4 shows the use of asthma-related inhalers that are found to be significantly higher in the CRSwNPs group than the CRSsNPs group (16% and 20% in CRSwNPs vs 8% and 9% in CRSsNPs for non-steroidal and steroidal inhalers, respectively (P < .001). This is, however, much lower than the reported rates of asthma in the two groups (21% and 51%).
| Asthma-related medications
| Non-CRS medications
Analysis of the remaining therapeutic groups noted some key differences between the two phenotypic groups as charted in Table 5 .
ACE-inhibitors and a-blockers were significantly more prevalent in CRSwNPs (P = .04, .03) and b-blockers, NSAIDs and opiate analgesics significantly more prevalent in CRSsNPs (P < .01).
| CRS and mood disturbances
The rates of depression and anxiety in CRS from the CRES have been reported elsewhere 18 ; however, it is pertinent to note that the reported rates of depression are much higher (20% in CRSwNPs and 25% in CRSsNPs) than the use of antidepressants themselves (Table 6 ); 7% in CRSwNPs and 13% in CRSsNPs.
| Qualitative study
The qualitative substudy found that patients reported issues with prescribed treatment in primary care 15 . Most participants described several courses of different, often ineffective treatments, which were not always reviewed. It was clear that referral to secondary care based on a lack of symptomatic response to 3 months of topical treatment did not always occur for our participants due to both patient and clinician preferences.
F I G U R E 1 participant flowchart
On and off I've used nasal sprays, it was a sort of a bit hit and miss really I might think 'oh it's a bit bad I'll go to the chemist and get something'.
I've now obviously got to do (a nasal spray) (after being seen in secondary care) but I've only ever had that once. . . a lot of the time. I would have antibiotics and that would clear it very briefly.
Most described several courses of different, often ineffective treatments, which were not always reviewed.
Everything I tried was so random.
I was put onto Betnesol nasal drops, remained on them until last year [without significant benefit. Patient had been on this treatment for 40 years].
There were negative views and misconceptions about topical medications.
The nasal sprays they make it a lot worse. . . it irritates my eyes and stuff to the point where I'm sneezing 100 If that cost £10 000 for an operation and that's £2000 for drugs they go for the cheap route.
| DISCUSSION
| Key results
The low prevalence of current use of CRS medication may reflect poor prescribing (including advice on how to best use topical treatments), poor adherence to the prescription or poor recall. It may also reflect the fact that sprays and rinses are more burdensome to use than taking tablets, as described in our qualitative interviews or that they are not seen as "proper" medications as they are sprays not tablets 15, 18 . Furthermore, it may simply be that patients have tried medical therapy but failed to derive significant benefit or did not tolerate them, so have stopped taking them.
| Strengths and limitations
The study is a large cross-sectional study including a varied population from across the United Kingdom. It is the largest research study of CRS in the UK to date. In contrast to other epidemiological studies in CRS, patients recruited were diagnosed by an otorhinolaryngologist according to international guidelines. The study design had some limitations, it was a self-reported study which predisposes to recall bias. It is possible that some patients may not have considered intranasal medications when asked about medication use; however, they have reported inhalers so we expect that the impact of this on the study findings is small. They may have also not considered ND as a regular medication; however, both our qualitative work and anecdotal evidence from GP meetings suggest that advice regarding ND in primary care is scarce and steam inhalation is more often recommended to patients. From qualitative interviews, we know that some found ND uncomfortable or difficult to integrate into the daily routine, but others are able to tolerate it and in fact may find it helpful 19 . The fact that the CRES data reflect medication use at one moment in time along the patient's journey is also a limitation.
| Interpretation
Looking at the wider picture, one international study demonstrated that one in three CRS patients in primary care has poorly controlled symptoms 20 ; the feedback from our participants in the qualitative substudy also highlighted poor symptom control as a With regard to non-CRS medications, use of steroid and nonsteroid inhalers was higher amongst those with CRSwNPs compared to those with CRSsNPs. This was likely to be due to their higher prevalence of asthma. Use of b-blockers and NSAIDs was lower in this group, which was also likely to be due to a higher prevalence of asthma (contra-indicated). Use of a-blockers was higher amongst CRSwNPs, and as it is mostly used for prostatic hypertrophy, the difference may be due to a male preponderance in this group. The difference in antidepressant use may reflect the fact that facial pain is more common in CRSsNPs and correlates with findings that mood and emotional well-being are poorer in this subgroup, as discussed with the qualitative results and in a separate analysis from CRES of mood disturbance in CRS 15, 18 .
| Generalisability
Inevitably these patients were referred to secondary care due to failure of primary care treatment and does not reflect those who were not referred. Primary care patients who have not been referred may all be managing well on INCS and therefore not needing a referral, whereas those where treatment does not work may be unlikely to continue with treatment. However, the population studied in CRES represents those who are typically managed within ENT clinics countrywide.
Adherence to medical regimens is an important issue, particularly in the management of chronic conditions. These findings are consistent with a World Health Organization report, which stated that, on average, 50% of patients are not adherent to long-term therapy for chronic illnesses. They stated that poor adherence is the primary reason for suboptimal clinical benefit in chronic diseases, causing medical and psychosocial complications of the disease, reducing quality of life and wasting healthcare resources 23 . Careful patient education may help improve this situation, including reassurance regarding the safety of long-term treatment with newer formulations of intranasal steroids that have very low systemic bioavailability.
Improved communication from ENT specialists to primary care regarding proposed treatment duration is also important.
| CONCLUSION
The reported use of baseline medical therapy in CRS appears to be very low. This is likely to represent a combination of poor patient compliance, possible perceived lack of effectiveness and a lack of familiarity with current guidelines amongst both general practitioners and some specialists despite national, European and International guidelines for the medical management of CRS in both primary and secondary care. Work is needed to understand any barriers to implementing guidelines including disseminating them to all practitioners involved in the care of CRS patients and to encourage good compliance with treatment including sound advice on usage of topical medications. Improvement of medical management may serve to reduce unnecessary burden on existing healthcare resources for this common condition by ensuring timely referral and definitive management when needed.
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O R C I D 
INSTRUCTIONS:
This set of questions ask for your views about your health. This information will help keep track of how you feel and how well you are able to do your usual activities.
Answer every question and mark your response by filling in the box thus:
If you are unsure how to answer a question, please give the best answer you can.
In general, would you say your health is: (Fill The following questions are about activities you might do in a typical day. Does your health now
Below you will find a list of symptoms and social/emotional consequences of your nasal disorder. We would like to know more about these problems and would appreciate your answering the following questions to the best of your ability. There are no right or wrong answers and only you can provide us with this information. Please rate your problems over the last two weeks.
Considering how severe the problem is when you experience it and how frequently it happens, please rate each item below on how "bad" it is by filling in the box that corresponds to how you feel. Thank you for taking part in this survey
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